X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (332) 332
index medicus (296) 296
colorectal cancer (280) 280
folfiri (278) 278
humans (276) 276
chemotherapy (253) 253
bevacizumab (225) 225
colorectal neoplasms - drug therapy (214) 214
leucovorin (184) 184
colorectal neoplasms - pathology (181) 181
female (179) 179
1st-line treatment (178) 178
fluorouracil (178) 178
male (178) 178
metastasis (171) 171
middle aged (168) 168
aged (163) 163
antineoplastic combined chemotherapy protocols - therapeutic use (159) 159
oxaliplatin (153) 153
cancer (151) 151
camptothecin - analogs & derivatives (137) 137
irinotecan (135) 135
cetuximab (131) 131
adult (127) 127
treatment outcome (112) 112
open-label (108) 108
fluorouracil - administration & dosage (107) 107
neoplasm metastasis (107) 107
folfiri plus bevacizumab (104) 104
camptothecin - administration & dosage (103) 103
metastatic colorectal cancer (96) 96
leucovorin - administration & dosage (92) 92
care and treatment (90) 90
disease-free survival (89) 89
survival (87) 87
antineoplastic combined chemotherapy protocols - adverse effects (84) 84
antineoplastic combined chemotherapy protocols - administration & dosage (79) 79
medicine & public health (71) 71
therapy (70) 70
aged, 80 and over (67) 67
trial (66) 66
combination (65) 65
colorectal neoplasms - mortality (64) 64
panitumumab (63) 63
drug therapy (61) 61
research (59) 59
colorectal neoplasms - genetics (57) 57
phase-iii (55) 55
organoplatinum compounds - administration & dosage (54) 54
analysis (53) 53
patients (53) 53
colorectal carcinoma (51) 51
metastases (51) 51
tumors (51) 51
antineoplastic agents (50) 50
hematology, oncology and palliative medicine (50) 50
folfox (49) 49
antimitotic agents (47) 47
camptothecin - adverse effects (47) 47
camptothecin - therapeutic use (47) 47
clinical trials (47) 47
cancer patients (46) 46
cancer therapies (46) 46
fluorouracil - therapeutic use (46) 46
liver neoplasms - secondary (46) 46
pharmacology & pharmacy (46) 46
fluorouracil - adverse effects (45) 45
retrospective studies (45) 45
survival rate (45) 45
leucovorin - adverse effects (43) 43
prognosis (43) 43
antibodies, monoclonal, humanized - administration & dosage (42) 42
antibodies, monoclonal - administration & dosage (41) 41
randomized-trial (41) 41
kaplan-meier estimate (40) 40
kras (40) 40
leucovorin - therapeutic use (40) 40
capecitabine (39) 39
mutation (39) 39
efficacy (38) 38
internal medicine (37) 37
phase-iii trial (37) 37
antineoplastic agents - therapeutic use (36) 36
multicenter (36) 36
ras mutations (36) 36
liver neoplasms - drug therapy (35) 35
randomized phase-iii (35) 35
cancer research (34) 34
infusional fluorouracil (34) 34
surgery (34) 34
plus irinotecan (33) 33
5-fluorouracil (32) 32
monoclonal antibodies (31) 31
angiogenesis inhibitors - therapeutic use (30) 30
digestive system diseases (30) 30
vascular endothelial growth factor (30) 30
antibodies, monoclonal - therapeutic use (29) 29
gastroenterology and hepatology (29) 29
liver metastases (29) 29
neoplasm staging (29) 29
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Clinical Oncology, ISSN 1341-9625, 2/2016, Volume 21, Issue 1, pp. 110 - 117
The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and... 
FIREFOX | Chemotherapy | Neurotoxicity | Medicine & Public Health | Colorectal cancer | Oncology | Cancer Research | FOLFOX6 | Surgical Oncology | FOLFIRI | LEUCOVORIN | STATISTICS | OPEN-LABEL | OXALIPLATIN | FLUOROURACIL | CETUXIMAB | THERAPY | ONCOLOGY | AVAILABILITY | IRINOTECAN | Leucovorin - administration & dosage | Thrombosis - chemically induced | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nausea - chemically induced | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Hypertension - chemically induced | Leukopenia - chemically induced | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Bevacizumab - administration & dosage | Survival Rate | Disease-Free Survival | Vomiting - chemically induced | Anorexia - chemically induced | Aged | Colorectal Neoplasms - pathology | Hypertension | Care and treatment | Clinical trials | Nausea | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Product development | Cancer | Index Medicus
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 510 - 7
Panitumumab and bevacizumab have been widely used in combination with chemotherapy for patients with wild type RAS metastatic colorectal cancer (mCRC). Whether... 
GROWTH-FACTOR RECEPTOR | CETUXIMAB | MULTICENTER | EFFICACY | RAS MUTATIONS | MULTIDISCIPLINARY SCIENCES | PHASE-III | 2ND-LINE TREATMENT | WILD-TYPE KRAS | FLUOROURACIL | FOLFIRI | Chemotherapy | Colorectal carcinoma | Colorectal cancer | Clinical trials | Metastasis | Survival | Bevacizumab | Metastases
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2018, Volume 29, Issue 7, pp. 1528 - 1534
Abstract Background Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from first-line doublets plus a... 
Primary sidedness | FOLFOXIRI plus bevacizumab | RAS and BRAF mutational status | Metastatic colorectal cancer | ANTIBODIES | LOCATION | 1ST-LINE TREATMENT | DISTAL | ONCOLOGY | RAS | primary sidedness | metastatic colorectal cancer | FOLFIRI
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2015, Volume 21, Issue 7, pp. 2096 - 2101
AIM:To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic... 
tract | cholangiocarcino | cancer;Intrahepatic | Biliary | Second-line treatment | Biliary tract cancer | Intrahepatic cholangiocarcinoma | Bevacizumab | FOLFIRI | BILIARY-TRACT CANCER | MULTICENTER | GALLBLADDER CARCINOMA | PHASE-II | OPEN-LABEL | OXALIPLATIN | COMBINATION | CHEMOTHERAPY | GEMCITABINE | GASTROENTEROLOGY & HEPATOLOGY | ERLOTINIB | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Tomography, X-Ray Computed | Bile Ducts, Intrahepatic - drug effects | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Time Factors | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | France | Angiogenesis Inhibitors - adverse effects | Bile Duct Neoplasms - drug therapy | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Bile Ducts, Intrahepatic - pathology | Drug Administration Schedule | Cholangiocarcinoma - secondary | Cholangiocarcinoma - mortality | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Bile Ducts, Intrahepatic - diagnostic imaging | Disease-Free Survival | Cholangiocarcinoma - diagnostic imaging | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bile Duct Neoplasms - mortality | Aged | Bile Duct Neoplasms - pathology | Bile Duct Neoplasms - diagnostic imaging | Retrospective Study
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2012, Volume 23, Issue 7, pp. 1693 - 1699
Journal Article
Journal Article
Cellular Physiology and Biochemistry, ISSN 1015-8987, 2018, Volume 48, Issue 5, pp. 1870 - 1881
Journal Article
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 2019, Volume 9, p. 142
Background: The prognosis of patients with metastatic colorectal cancer (mCRC) is poor, especially after failure of initial systemic therapy. The VELOUR study... 
MCRC | Colorectal cancer | Metastasis | Disease control | Ziv-aflibercept | FOLFIRI | ZFOLFIRI | zFOLFIRI | PLACEBO | MULTICENTER | colorectal cancer | BIOMARKER | VEGF | OXALIPLATIN | COMBINATION | ziv-aflibercept | THERAPY | ONCOLOGY | mCRC | metastasis | disease control | AGENTS | Usage | Leucovorin | Dosage and administration | Research | Drug therapy, Combination | Drug therapy
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 04/2013, Volume 108, Issue 8, pp. 1566 - 1570
Background: Preoperative treatment of resectable liver metastases from colorectal cancer (CRC) is a matter of debate. The aim of this study was to assess the... 
neoadjuvant | colorectal cancer | THERAPY | ONCOLOGY | RESECTION | bevacizumab | OXALIPLATIN | liver metastases | CHEMOTHERAPY | FOLFIRI | surgery
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 73, pp. 74 - 84
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2012, Volume 106, Issue 3, pp. 453 - 459
Journal Article